Jpmorgan Chase & CO Replimune Group, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Replimune Group, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 486,609 shares of REPL stock, worth $5.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
486,609
Previous 249,349
95.15%
Holding current value
$5.6 Million
Previous $2.73 Million
115.67%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding REPL
# of Institutions
161Shares Held
74.9MCall Options Held
38.4KPut Options Held
43.7K-
Baker Bros. Advisors LP New York, NY11MShares$127 Million1.48% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11MShares$126 Million0.02% of portfolio
-
Redmile Group, LLC San Francisco, CA4.91MShares$56.4 Million4.65% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$54.2 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.97MShares$45.7 Million8.12% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $567M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...